Glucagon-like peptide-1: difference between revisions
Diff·revision 29 → 30·13:30, 9 Oct 2025
Difference between revision 29 and revision 30 of Glucagon-like peptide-1. 2 lines changed; the page grew by 192 bytes.
| Revision 29 — 20:50, 12 Sep 2025 ProglucagonPia (talk) the article treated a rodent finding as human physiology; corrected 12,102 bytes ±0 | Revision 30 — 13:30, 9 Oct 2025 TechnicianTeal (talk) add see also to the sister hormone 12,294 bytes +192 | ||
|---|---|---|---|
| 83 | The pathway is targeted clinically in three ways: degradation-resistant peptide agonists ([[exenatide]], [[liraglutide]], [[dulaglutide]], [[semaglutide]]), enzyme inhibition (the DPP-4 inhibitor class), and non-peptide agonists suitable for oral administration ([[orforglipron]]). Multi-receptor constructs extend the approach to GIP ([[tirzepatide]]), glucagon ([[survodutide]], [[retatrutide]]) and [[Amylin receptor agonist|amylin]] ([[CagriSema]]) co-agonism. | 83 | The pathway is targeted clinically in three ways: degradation-resistant peptide agonists ([[exenatide]], [[liraglutide]], [[dulaglutide]], [[semaglutide]]), enzyme inhibition (the DPP-4 inhibitor class), and non-peptide agonists suitable for oral administration ([[orforglipron]]). Multi-receptor constructs extend the approach to GIP ([[tirzepatide]]), glucagon ([[survodutide]], [[retatrutide]]) and [[Amylin receptor agonist|amylin]] ([[CagriSema]]) co-agonism. |
| 84 | 84 | ||
| + | 85 | {{note|Several peptides discussed elsewhere on this wiki are distributed only as research chemicals and are not approved for human use in any major jurisdiction. See [[Research use only]].}} | |
| + | 86 | ||
| 85 | == References == | 87 | == References == |
| 86 | {{reflist}} | 88 | {{reflist}} |